Photo of Filippo Montemurro taken from www.irccs.com
Jun 20, 2024, 11:37
Filippo Montemurro: Intriguing preclinical findings of synergy between fulvestrant and capecitabile in ESR1 tumors
Filippo Montemurro, Senior Medical Director at Roche, shared on X:
Pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer. Very intriguing preclinical findings of synergy between fulvestrant and capecitabile in ESR1 mutant tumors.
Read further
Source: Filippo Montemurro/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 22, 2025, 16:16
Feb 22, 2025, 16:04
Feb 22, 2025, 16:00
Feb 22, 2025, 15:54
Feb 22, 2025, 15:48
Feb 22, 2025, 15:33
Feb 22, 2025, 15:14
Feb 22, 2025, 15:04
Feb 22, 2025, 14:43
Feb 22, 2025, 14:10
Feb 22, 2025, 13:28
Feb 22, 2025, 13:10